<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04210453</url>
  </required_header>
  <id_info>
    <org_study_id>4-2019-1051</org_study_id>
    <nct_id>NCT04210453</nct_id>
  </id_info>
  <brief_title>The Impact of Vitamin C on Postoperative Acute Kidney Injury in Risk Patients Undergoing Valvular Heart Surgery</brief_title>
  <official_title>The Impact of Vitamin C on Postoperative Acute Kidney Injury in Risk Patients Undergoing Valvular Heart Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In cases of cardiac surgery or sepsis which cause inflammation, oxidative stress, endothelial
      injury and vasoplegia, serum vitamin C concentration is sharply decreased. The
      anti-inflammatory and anti-oxidant effects of vitamin C and the effects of reducing
      vasoconstrictor use have been demonstrated in patients with sepsis and septic shock, however,
      the foregoing effects have not been validated in patients undergoing cardiac surgery.

      In this study, investigators investigate the effect of intravenous vitamin C on the incidence
      of acute renal injury after valvular heart surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients are divided into 2 groups, who are administered IV Vitamin C or who are administered IV normal saline.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Neither participants, all care providers, investigators nor outcomes assessors know the treatment allocations.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative acute kidney injury</measure>
    <time_frame>Postoperative 7 days</time_frame>
    <description>Compare the incidence of postoperative acute kidney injury between the Vitamin C group and the control group according to KDIGO guideline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative oxidative stress and vascular injury(Comparing the serum concentration)</measure>
    <time_frame>Before anesthetic induction (Baseline)</time_frame>
    <description>Compare the serum concentration of Malondialdehyde, Thrombomodulin before anesthetic induction and after CPB cessation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative oxidative stress and vascular injury(Comparing the serum concentration)</measure>
    <time_frame>5 minute after CPB cessation</time_frame>
    <description>Compare the serum concentration of Malondialdehyde, Thrombomodulin before anesthetic induction and after CPB cessation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this group are administered IV normal saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin C group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group are administered IV vitamin C diluted in normal saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>Participants in &quot;Vitamin C group&quot; are administered IV vitamin C diluted in 100 cc normal saline 1 day before surgery, at rewarming during surgery, 3 hours after surgery, and every 6 hours thereafter until postoperative 24 hours.</description>
    <arm_group_label>Vitamin C group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control (Normal saline)</intervention_name>
    <description>Participants in &quot;Control group&quot; are administered IV 100cc normal saline at the same timepoint as above.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 20 years and undergoing elective valvular heart surgery whose
             preoperative acute renal failure score is â‰¥3 (moderate to severe risk).

        Exclusion Criteria:

          -  Emergency operation

          -  Cardiogenic shock or ventricular-assist device (eg. ECMO, IABP)

          -  Severe chronic kidney disease (GFR(CKD-EPI) &lt;30ml/min/1.73m2)

          -  Patients with past history of gout or renal stone or hyperoxaluria or cystinuria

          -  Hemolytic anemia due to pyruvate kinase deficiency or glucose-6-phosphate
             dehydrogenase deficiency

          -  Sicklemia or thalassemia

          -  Hemochromatosis

          -  Allergy to disodium ethylenediamine-tetraacetate or ascorbic acid

          -  Patients taking aspirin up to 3 days before surgery

          -  Patients taking antiepileptic drug or fluphenazine or steroid

          -  Patients taking vitamin C within a month of surgery

          -  Pregnant or lactating women

          -  Patients who cannot understand the informed consent (eg. Foreigner)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hye Bin Kim</last_name>
    <phone>82-2-2224-1242</phone>
    <email>KAKDDUGI@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Anesthesiology and Pain Medicine Anesthesia and Pain Research Institute, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hye Bin Kim</last_name>
      <phone>82-2-2224-1242</phone>
      <email>KAKDDUGI@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postoperative acute kidney injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

